|
Mechanism- |
|
|
|
Inactive Indication- |
Drug Highest PhaseDiscovery |
First Approval Ctry. / Loc.- |
First Approval Date- |
A Phase 3, Randomised, Placebo-Controlled Trial of Arimoclomol in Amyotropic Lateral Sclerosis
A multicenter, randomized, double-blind, placebo-controlled, parallel group trial to evaluate the efficacy and safety of arimoclomol in amyotropic lateral sclerosis (ALS)
/ Not yet recruitingPhase 2/3 Arimoclomol prospective double blind, randomised, placebo-controlled study in patients diagnosed with Niemann Pick disease type C - Investigate study drug Arimoclomol with patients diagnosed with Niemann Pick disease type C.
100 Clinical Results associated with Zevra Denmark as
0 Patents (Medical) associated with Zevra Denmark as
100 Deals associated with Zevra Denmark as
100 Translational Medicine associated with Zevra Denmark as